Pluristem Files Patent Application For PLX-1

GEN reports from Biowire: Pluristem Life Systems, Inc. , a cell therapy company dedicated to the commercialization of stem cell products, today announced that a patent application has been filed with the US Patent and Trademark Office for its stem cell therapy product known as PLX-1. PLX-1 is intended to offer a breakthrough solution to improved engraftment during bone marrow transplant procedures that use umbilical cord blood (UCB).

PLX-1, which consists of propagated (adjuvant engineered) mesenchymal stem cells (MSC) that can be co-transplanted along with the hematopoietic stem cells (HSC), is expected to significantly improve the engraftment rate of the HSCs.

The role of PLX-1 is to improve the homing of hematopoietic stem cells and their lodgment into the patient hematopoietic niche using engineered mesenchymal cells. This new technology is based on using Pluristem's ex vivo expanded Engineered Mesenchymal Cells (EMC) that are expanded within the proprietary PluriX(TM) high density 3-D cultures system.

**
Elsewhere, it has been suggested that different patents/applications of Pluristem might be involved in interferences with those of UWisconsin.